IP Library Patent Application 10566282
Patent Application
App. No. 10/566,282

Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis-regulating medicaments and method for the preparation thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/566,282
Abstract

The present invention relates to thiomorpholino steroid compounds of general formula I, which may advantageously be employed to stimulate meiosis in human oocytes, the steroid being specifically characterized by a thiomorpholino moiety bonded to C 17 of the steroid skeleton via an alkylen spacer.

Claims (29)

1 . A thiomorpholino steroid compound of general formula I

wherein in the moiety I′ of compound I

each bond between between C 5 and C 6 , between C 6 and C 7 , between C 7 and C 8 , between C 8 and C 9 , between C 8 and C 14 and between C 14 and C 15 , independently, is a single bond or a double bond, at least one of these bonds being a double bond, with the proviso that there is no double bond in the steroid skeleton exclusively between C 5 and C 6 , and

wherein

R 4 and R 4′ independently, are selected from the group, comprising hydrogen and methyl.

2 . The steroid compound according to claim 1 , wherein in the moiety with general formula I′ one double bond is present between C 8 and C 14 or two double bonds are present between C 8 and C 9 and between C 14 and C 15 or two double bonds are present between C 5 and C 6 and between C 7 and C 8 .

3 . The steroid compound according to claim 1 , being selected from the group comprising:

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5α-pregna-8,14-dien-3β-ol:

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5α-pregna-8(14)-en-3β-ol:

(20S)-20-[(thiomorpholin-4-yl)methyl]-5α-pregna-8,14-dien-3β-ol:

(20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-pregna-5,7-dien-3β-ol

(20S)-20-[(thiomorpholin-4-yl)methyl]-5α-pregna-8(14)-en-3β-ol:

4 . A pharmaceutical composition comprising at least one thiomorpholino steroid compound of general formula I according to claim 1 and at least one pharmaceutically acceptable excipient.

5 . The pharmaceutical composition according to claim 4 , wherein the steroid compound of general formula I is comprised in an effective amount.

6 . A use of the thiomorpholino steroid compound of general formula I according to claim 1 to the preparation of a pharmaceutical composition being useful to regulate reproduction, especially meiosis.

7 . The use according to claim 6 for non-in vivo use.

8 . A use of the thiomorpholino steroid compound of general formula I according to claim 1 to the preparation of a contraceptive or of a profertility drug.

9 . A method of regulating reproduction, especially meiosis, comprising administering to a subject in need of such a regulation an effective amount of at least one thiomorpholino steroid compound of general formula I according to claim 1 .

10 . A method for improving the possibility of an oocyte's ability to develop into a mammal, comprising contacting an oocyte removed from the mammal with the thiomorpholino steroid compound according to claim 1 .

11 . A method for the preparation of (20S)-20-[(thiomorpholin-4-yl)methyl]-4,4-dimethyl-5α-pregna-8,14-dien-3β-ol, comprising

a) starting from (20S)-20-hydroxymethyl-pregna-4-en-3-one;

b) introducing two alkyl groups in C 4 by alkylation;

c) reducing the keto group to a hydroxy group;

d) protecting the resulting hydroxy group with an acyl group;

e) introducing a Δ 7 double bond by bromination/dehydrobromination;

f) isomerizing the dien Δ 5,7 to the dien Δ 8,14 by heating in the presence of acid;

g) oxidizing the 17-hydroxy group to an aldehyde group;

h) reductively aminizing the aldehyde group with thiomorpholine and removing the acyl group by reduction reaction

12 . The method according to claim 11 , wherein the acyl group is a benzoate group.

Assignments (2)
CHANGE OF NAME Recorded Nov 14, 2007
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 020110/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2006
From: BLUME, THORSTEN; LINDENTHAL, BERNHARD; PRELLE, KATJA; PETERS-KOTTIG, MICHAELE
To: SCHERING AKTIENGESELLSCHAFT
Reel/Frame 018023/0693 →